Two cases of solitary plasmacytoma of bone (SPB) were diagnosed. The first case was a 41-year-old woman, complaining of fatigue from her lumbar region to her legs. The second case was a 56-year-old man complaining of poor gait and severe lumbago with numbness in the toes of both feet. Magnetic resonance imaging showed the osteolytic lesion in the 12th thoracic bone in the first patient and around the 2nd, 3rd and 4th lumbar bones in the second patient. In both patients serum analysis revealed the monoclonal component of immunoglobulin G (IgG) protein with k-light chain, and considering this and other findings SPB was diagnosed. Both patients were first treated with irradiation around the involved bone and then with a course of chemotherapy. In the first patient the tumour region of the bone was surgically removed and replaced with a ceramic spacer. The symptoms of both patients were ameliorated, and the patients remained in good condition for around 3 years without conversion to multiple myeloma. In view of the overall effectiveness of treatments for SPB, our therapeutic strategy deserves careful evaluation.
Introduction
A solitary plasmacytoma of bone (SPB) is found in perhaps 2 -10% of patients with multiple myeloma (MM). It appears most often as a cystic, soap-bubble-type lesion that is larger and more irregular than the small, discrete lesions characteristic of MM. SPB has the appearance of a solitary, destructive lesion within the medullary portion of the bone. Rarely, new bone formation is seen. Although solitary lesions have in the past been regarded as comparatively benign, most patients have monoclonal components in the serum and develop diffuse plasma-cell myeloma when followed for long periods, even when the original lesion was radically excised or irradiated. Before making a diagnosis of SPB, a sample of bone marrow from an area at a distance from the single lesion should be examined, and careful long-term clinical follow-up is essential. 1 Extramedullary plasmacytoma is a mass of plasma cells remote from the bone marrow and is considered a variant of multiple myeloma. 2 It is differentiated from SPB based on the site of involvement and the rate of conversion to MM, conversion being more rapid in extramedullary plasmacytoma. 3 We report below two cases of SPB in lumbar and thoracic vertebrae with monoclonal component of immunoglobulin G 
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(κ-light chain type) in the serum. In the first patient the tumour region of the thoracic bone was excised after irradiation and then the patient received further irradiation and a course of chemotherapy. The second patient was treated with radiation and a course of chemotherapy. Our strategies for the evaluation and therapy of these cases with SPB are documented.
Case reports CASE 1
A 41-year-old female had been complaining of fatigue extending from her lumbar region to her leg. Investigation showed an abnormal shadow in the 12th thoracic bone on 11 August 1997. On 16 September 1997, a biopsy was taken and B-cell neoplasm compatible with plasmacytoma was diagnosed. Bone-marrow puncture findings revealed 4.7% plasma cells. One punchedout shadow was recognized in the skull. Bence-Jones protein was detected in the urine. Laboratory and haematological data are shown in Tables 1 and 2. A diagnosis of SPB was made considering all of the available data. After diagnosis the patient was transferred to our hospital on 21 October 1997 for operation, radiation therapy and chemotherapy. The 12th thoracic bone, which was involved in the tumour, was irradiated to a total count of 2160 cGy fractionally from 14 November to 21 November 1997, and the tumour region of the 12th thoracic bone was excised and replaced with a ceramic spacer to fix the spine on 12 December 1992. The region of the 12th thoracic bone was irradiated with a total count of 3600 cGy fractionally between 14 November 1997 and 29 January 1998. Combinations of chemotherapy and interferon-α2b, as described in Table 3 , were given, and the patient's clinical symptoms and laboratory data improved. The patient was discharged on 14 March 1998. She was further admitted to hospital from 6 November 1998 to 1 December 1998, and from 8 to 28 July 1999 for consolidation therapy with ranimustine 70 mg/day × 1 day, vincristine 2 mg/day × 1 day, melphalan 12 mg/day × 6 days, dexamethasone 40 mg/day × 12 days intermittently and interferon-α2b 3 × 10 6 U/day × 20 days (Table 3 ). After discharge from hospital, the patient's clinical symptoms were followed in our out-patient clinics, but no abnormal findings or other tissue involvement, except for the presence of monoclonal immunoglobulin component immunoglobulin G (κ-light chain type), as shown by the changes of monoclonal immunoglobulin G levels during her clinical course, were observed ( Fig.1 ).
CASE 2
A 56-year-old man presented to another hospital complaining of poor gait and severe lumbago accompanied by numbness in the toes of both feet at the end of May 1997. Magnetic resonance imaging showed an abnormal shadow in the lumbar vertebrae. The patient was admitted to our hospital for irradiation of the involved lumbar vertebrae. Bone-marrow examination showed plasma cells including a few atypical myeloma cells as shown in Table 4 . The patient was 162 cm in height and 46 kg in body weight. Chest and abdominal findings were almost normal. Laboratory data were almost normal except for the presence of the monoclonal component of immunoglobulin G (κ-light chain type) in the serum on immunofixation electrophoresis. The karyotype of bone-marrow cells was 46 XY. The 2nd, 3rd and 4th lumbar vertebrae were irradiated with a total count of 4140 cGy fractionally, 180 cGy × 23 days, from 31 July 1997 to 22 August 1997. After irradiation, the chemotherapy regimen of ranimustine 70 mg/day × 1 day, vincristine 2 mg/day × 1 day, melphalan 12 mg/day × 6 days, dexamethasone 40 mg/day × 12 days intermittently and interferon-α2b 3 × 10 6 U/day × 20 days was started on 27 August 1997. The patient was discharged due to amelioration of bone pain and decreased abnormal serum immunoglobulin levels on 5 December 1997. 
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Intensive consolidation therapy with ranimustine 70 mg/day × 1 day, vincristine 2 mg/day × 1 day, melphalan 12 mg/day × 6 days, dexamethasone 40 mg/day × 12 days intermittently and interferon-α2b 3 × 10 6 U/ day × 20 days was undertaken during further periods of hospitalization from 7 April to 6 May 1998, from 6 November to 1 December 1998, from 1 February to 3 March 1999 and from 24 May to 24 July 1999. The patient's clinical condition was good and concentrations of monoclonal component immunoglobulin G gradually decreased (Fig. 2) concurrently with the improvement of clinical symptoms. During follow-up in outpatient clinics until 16 December 2000 the patient showed no further symptoms similar to those seen at the first hospitalization.
Discussion
These two cases were maintained in a good clinical condition for about 3 years, albeit with low concentrations of monoclonal immunoglobulin G component (κ-light 2, 3 Our cases did not convert to MM without bone-marrow invasion, although a few plasma cells were found in the bone marrow. Within both disease types the achievement of local control of spinal-cord compression is an important management priority, without which survival may be adversely affected. 4 Case 2 complained of numbness in the toes of both feet, which was eliminated after irradiation and chemotherapy. This study attempted to clarify the clinical course of SPB after radiation or surgical therapy given with curative intent. The diagnosis was based on a mass of clonal plasma cells separate from bone or bone marrow without evidence of occult disease elsewhere. Both patients underwent irradiation of a plasmacytoma of involved bone, plus chemotherapy. Radiation therapy has previously resulted in excellent local control of SPB with an approximate cure rate of 50%. 5 Plasmacytoma of the spine is quite common, but solitary occurrence is not. 6 Takahashi et al. 7 reported two cases of SPBs in the thoracic spine. The tumours, which were diagnosed by histopathology as plasmacytomas, were removed and the patients' symptoms improved. Our diagnoses were also based on the findings of bone-marrow puncture, histopathology and immunoelectrophoresis. Cervoni et al. 8 reached diagnoses, in their studies of 15 patients, on the basis of the following: histologically confirmed plasmacytoma following surgical removal; the existence of a single vertebral lesion, documented by skeletal MRI scan; and no signs at diagnosis of disseminated disease by blood laboratory test, urine analysis, sternal puncture, iliac K Ota, T Tsuda, N Katayama et al. 8 Based on the therapeutic study of Chang et al., 9 it is recommended that irradiation of the primary sites is the treatment of choice. Chemotherapy is indicated in patients with disease progression. Treatment in cases of SPB in mastoid bone consists of radiotherapy. In cases of localization of MM in the mastoid bone, the treatment consists of palliative chemotherapy. 10 Strict staging criteria, including normal magnetic resonance imaging studies of the axial skeleton and the long bones and absence of monoclonal plasma cells detected by flow cytometry or polymerase chain reaction, are needed to diagnose SPB. 11 Radiotherapy at a dose of 4500 cGy is used to eradicate the local tumour. Many patients enjoy prolonged disease-free survival, but systemic relapse frequently occurs. If strict diagnostic criteria are applied, however, some patients are expected to be cured. 11 Although local control rates for SPB after radiotherapy are excellent, progression to MM is frequent, albeit with varying latency. Local failure in the absence of dissemination, however, is rare. A recent report documents the case of a patient who presented 3 years after local radiation for a pelvic SPB and was successfully treated with orthopaedic surgery. 12 This treatment resulted in good pain relief and mobility for the patient, who remained free of disease 6 months after the operation. 12 In a study of the natural history of SPB after irradiation 57 patients with previously untreated SPB, treated between 1965 and 1996, were identified. 13 A serum myeloma protein was present in 33 patients (58%) and Bence-Jones proteinuria was present in an additional eight patients (14%). Local control was achieved after radiotherapy (median dose 50 Gy) in 55 of 57 (96%). For the 29 patients (51%) who subsequently developed MM, the median time to progression was 1.8 years.
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There was a direct correlation between persistence of abnormal protein following radiotherapy and the likelihood of developing MM. Among 23 patients with thoracolumbar spine disease, seven of eight patients staged with plain radiographs alone developed MM in comparison with one of seven patients who also had magnetic resonance imaging. For all patients, the median survival from radiotherapy was 11 years. The median causespecific survival of patients with disappearance of myeloma protein was significantly longer than that of the remaining patients (P = 0.004). These results emphasize the importance of precise staging that includes magnetic resonance imaging of the spine for optimum patient selection and the application of definitive radiotherapy. Those patients with myeloma protein that disappears following radiotherapy represent a category with a high likelihood of cure. 13 The two cases with SPB reported above were treated with surgical removal, irradiation and chemotherapy. Despite the presence of monoclonal component immunoglobulin G (κ-light chain) in the serum, both patients have been maintained in good clinical condition for around 3 years. We believe that this therapeutic strategy deserves further evaluation.
